BBIO

BridgeBio Pharma's (BBIO) heart disorder drug Attruby faces near-term tailwinds from the likely appr

The headline numbers for BridgeBio Pharma (BBIO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

If you had bought BridgeBio Pharma on 19 October 2025, you now have a very specific outcome to measure against that choice. For BridgeBio Pharma shareholders, the return over the past year was 20.8%, including dividends.

BridgeBio Pharma (BBIO) is back in focus after new real world data on its ATTR-CM drug acoramidis showed replicated benefits on clinical worsening events, including heart failure hospitalizations and mortality, compared with tafamidis.

BridgeBio Pharma has seen its share price move sharply over recent years, and with a market value now anchored more to expectations than current profits, the key issue is how far its sales can justify where the stock trades today.

BridgeBio Pharma reported fresh clinical and regulatory milestones for acoramidis, encaleret, and oral infigratinib, including real-world ATTR-CM effectiveness data, Phase 3 CALIBRATE outcomes in ADH1, and FDA Priority Review for infigratinib in pediatric…

BridgeBio Pharma (NasdaqGS:BBIO) reported new real world and expanded clinical data for acoramidis in ATTR-CM, showing benefits versus tafamidis across multiple datasets.

BridgeBio Pharma (BBIO), Madrigal Pharmaceuticals (MDGL) and Cytokinetics (CYTK) traded meaningfully

BridgeBio Pharma (BBIO) reported Sunday a new phase 3 trial showing its investigational therapy enca